AFP and hepatocellular carcinoma: In order to systematically examine the performance of mSEPT9, AFP and PIVKA-II in HCC detection in HCC high-risk population, we first established a training cohort by recruiting 103 HCC and 114 HC patients following the inclusion, exclusion criteria and the recruiting flow chart (Table 1; Fig. 1).